Breaking Finance News

Ionis Pharmaceuticals Inc (NASDAQ:IONS) target price raised to $48.00, reported today by BMO Capital Markets

Just yesterday Ionis Pharmaceuticals Inc (NASDAQ:IONS) traded 0.00% even at $36.38. Ionis Pharmaceuticals Inc’s 50-day moving average is $32.65 and its 200-day moving average is $32.31. The last closing price is up 6.04% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,836,847 shares of IONS traded hands, down from an average trading volume of 2,329,540

Ionis Pharmaceuticals Inc (NASDAQ:IONS) had its stock price target raised to $48.00 by BMO Capital Markets in a report released Thursday October 06, 2016. The new target suggests a potential upside of 0.32% based on the company's most recent close.

Recent Performance Chart

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Ionis Pharmaceuticals Inc has 52 week low of $19.59 and a 52 week high of $65.34 and has a market capitalization of $0.

In addition to BMO Capital Markets reporting its stock price target, a total of 9 brokers have issued a research note on the company. The average stock price target is $52.56 with 1 brokerage rating the company a strong buy, five brokerages rating the company a buy, five brokerages rating the company a hold, zero brokerages rating the company a underperform, and lastly 1 firm rating the stock a sell.

General Information About Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *